Cellbricks Secures $10M
Berlin‑based Celicks announced a $10 million financing round aimed at accelerating its proprietary 3D bioprinting platform for vascularized tissue implants. The capital will fund the transition of its lead programs from pre‑clinical studies into early‑stage clinical trials, positioning the startup at the forefront of regenerative‑medicine research. Celicks’ technology prints living tissue with built‑in blood‑vessel networks, addressing the long‑standing bottleneck of vascularization that has limited the viability of engineered organs. By creating functional, perfusable constructs, the company hopes to offer an alternative to donor grafts for organs such as kidneys, livers, and endocrine glands, which are critical in both standard and longevity‑focused medicine. The founder emphasized that “functional tissue replacement is a genuine bottleneck in longevity medicine,” noting that even with anti‑aging interventions, organ failure remains inevitable without viable substitutes. Successful vascularization could therefore shift the trajectory of age‑related organ decline and expand therapeutic options beyond scarce donor organs. If Celicks validates its approach in humans, the implications are profound: reduced reliance on organ donation, accelerated drug development pipelines that require human‑like tissue models, and a new market segment for personalized regenerative therapies. Investors and healthcare systems alike will watch closely as the company moves toward clinical validation.
Eli Lilly’s Longevity Bet
Eli Lilly is quietly reshaping its R&D agenda, moving from a narrow GLP‑1 obesity play toward a broader longevity strategy. The company’s recent moves signal an ambition to become a “big farmer” of age‑related therapeutics, even if the term does not...
Early Brain Screening Expands
Premas, a neuro‑tech firm, has announced a partnership with Health is One to roll out its early‑brain‑screening platform across the health‑system network. The initiative focuses on detecting neurodegenerative disease risk factors before patients exhibit any clinical signs. The screening leverages proprietary...
US OTCQB Trading - Abingdon Health's Growth and Profitability Plan
Abingdon Health announced it will commence trading on the U.S. OTCQB market in April, extending its existing listing on the AIM exchange. The move follows the opening of a manufacturing facility in Madison, Wisconsin, a state known for its health‑tech...
Can Aging Be Treated Like a Disease? | Longevity News Roundup — Week 14, 2026
The Longevity Technology Unlocked episode spotlights four converging developments: PMAZ’s partnership with Health is One to roll out an early‑brain‑screening platform, Eli Lilly’s expanding multi‑pathway longevity portfolio, Berlin‑based Cell Bricks securing $10 million for vascularized bioprinted tissue implants, and coordinated global rallies...
Increasing Productivity in Clinical Research - Life Sciences Today Podcast Episode 48
Life Sciences Today host Danny Lieberman interviews Zena Sarif, founder of Yandu, about the chronic inefficiencies that prolong clinical‑trial timelines and how her startup aims to streamline the process. Sarif explains that up to 12‑18 months of a drug’s development are...
Abingdon's Latest Contracts Show Huge Diagnostic Test Breakthroughs
Abingdon announced two major contracts—a $2.5 million U.S. agreement to manage an international clinical diagnostic program and a £4.8 million UK deal to develop multiplex lateral‑flow tests—underscoring its shift toward a full‑service diagnostic offering. The first contract funds Abingdon’s oversight of a clinical...
Session 3.1 - RISE Together: Data Sharing Across the Rare Disease Ecosystem
The RISE Together Session 3.1 convened experts to explore data‑sharing strategies across the rare‑disease ecosystem, using amyotrophic lateral sclerosis (ALS) as a pilot. Panelists Colin Hovinga of the Critical Path Institute and Natanya Kerper of the Cystic Fibrosis Foundation highlighted...
High-Resolution Pan-Viral Antibody Profiling and Brain Health in People with HIV
Dr. Patricia Katie Riggs presented her latest research on high‑resolution panviral antibody profiling and its relationship to brain health in people living with HIV, emphasizing well‑controlled patients and the role of chronic co‑infections. Using a molecular indexing of proteins (MIP‑A) platform,...
Inside the Phased, Risk-Based Approach for CGT Materials
The video focuses on Bio4’s phased, risk‑based strategy for addressing particulate contamination in cell and gene therapy (CGT) raw and starting materials, a gap that has long plagued the industry. Bio4 is assembling a subgroup to draft best‑practice guidance, potentially...
Artemis II’s AVATAR and a Sungrazing Comet - Planetary Radio
The episode of Planetary Radio focuses on NASA’s Artemis II mission, highlighting the Avatar organ‑chip experiment and the imminent passage of a sungrazing comet. It introduces Lisa Carnell, director of NASA’s Biological and Physical Sciences Division, and astronomer Alan Mori discussing...
Rare Disease Day 2026 | Gene Therapy in Practice
The Rare Disease Day 2026 session titled “Gene Therapy in Practice” highlighted Johns Hopkins’ emerging program to deliver gene‑based treatments for pediatric neuromuscular disorders. Speakers—Dr. Jessica Nance, nurse practitioner Maria Belellios, and pharmacy coordinator Danielle Pennock—outlined the institution’s clinical‑trial legacy,...
Rare Disease Day 2026 | From Odyssey to Innovation, A Rare Journey to N of 1 Trial
Rare Disease Day 2026 highlighted a deeply personal yet broadly instructive case: the journey of Heidi, a patient with adult polyglucosan body disease (APBD), from a prolonged diagnostic odyssey to the launch of an N‑of‑1 clinical trial. The session brought...
Poolbeg Pharma: What Are the Next Steps?
Poolbeg Pharma used the briefing to detail its strategic roadmap, focusing on two parallel tracks – expanding its intellectual‑property holdings worldwide and advancing a pivotal clinical study in relapsed‑refractory multiple myeloma. The company said it will tap the Patent Prosecution Highway...
Riccardo Papa | On the Molecular Logic Underlying the Blueprint of Life - Lightning Talk @ VW 2026
In a five‑minute lightning talk at VW 2026, Riccardo Papa, a biology professor at the University of Puerto Rico, outlined his team’s ambitious quest to decipher the molecular “blueprint” of life. Using tropical butterflies as a tractable model, the project...
Philip Linden | Space Time Card @ Vision Weekend Puerto Rico 2026
Philip Linden presented the EPIC (Epoch of Time) initiative, a collaboration between the Open Lunar Foundation, Microchip and RIT, to develop a “space‑time card” – a compact, atomic‑clock‑based hardware module designed to provide precise timing on the Moon. The card,...
👉 Is Stem Cell Therapy or PRP Right for You? 💉 | Dr. Drew Timmermans
The ReadyState podcast episode with Dr. Drew Timmermans explains orthobiologic treatments—PRP and autologous stem cell therapy—as alternatives to surgery for musculoskeletal injuries. He defines PRP as platelet‑rich plasma derived from a patient’s blood, concentrated to deliver growth factors that restart the...
Advancing the Genesis Mission Through AI-Enabled Biological Discovery
The video introduces the Department of Energy’s Orchestrated Platform for Autonomous Laboratories (Opel), a cross‑lab initiative designed to accelerate AI‑enabled biological discovery and support the broader Genesis mission. Four national laboratories—Oak Ridge, Argonne, Pacific Northwest, and Lawrence Berkeley—are pooling expertise...
Poolbeg Pharma: Tell Us About This Patent?
Poolbeg Pharma announced that IP Australia has issued a formal certificate of grant for its patent covering the use of any P38 MAPK inhibitor, including its lead oral candidate pod001, to prevent cancer‑immunotherapy‑induced cytokine release syndrome (CRS). The approval...
451: The Latest In Plant Gene Editing with Pairwise COO
The Modern Acre podcast featured Ian Miller, COO of Pairwise, outlining the company’s CRISPR‑based gene‑editing platform that is delivering seedless blackberries and pitless cherries. Miller emphasized that Pairwise does not sell seeds directly; instead it licenses the proprietary varieties and...
Dr. Glaucomflecken Explains: Oral PCSK9 Inhibitor Enlicitide (CORALreef Lipids)
The video features Dr. Glaucomflecken discussing a new oral PCSK9 inhibitor, Enlisticide, and its recent New England Journal of Medicine publication. The drug targets patients with familial hypercholesterolemia or elevated LDL—specifically those with prior cardiovascular events (LDL > 55 mg/dL) or at high...
Where Will Regeneron Stock Be in 5 Years?
The Motley Fool Scoreboard episode focused on Regeneron Pharmaceuticals (REGN), assigning the company an overall rating of 7.8 out of 10 and projecting modest upside over the next five years. Analysts Keith Speights and Karl Thiel evaluated the business, management,...
Investing In Early-Stage Oncology With Yosemite's Dan McHugh
The Business of Biotech episode spotlights Dan McHugh, head of the investment team at Yosemite, a San Francisco‑based venture firm founded by Reed Jobs and Loren Powell Jobs. Yosemite’s mandate is to fund early‑stage cancer‑therapeutics developers, leveraging a mission‑driven capital pool that grew out of...
Original Article: Atezolizumab Plus FOLFOX for Stage III Colon Cancer (ATOMIC)
The phase 3 ATOMIC trial evaluated resected stage III mismatch‑repair‑deficient (dMMR) colon cancer patients receiving modified FOLFOX6 with or without atezolizumab. Adding atezolizumab improved three‑year disease‑free survival compared with chemotherapy alone. However, grade 3‑4 adverse events increased, driven primarily by fatigue. The findings...
Theravance's Strategic Review with Andy Summers $TBPH
Theravance Biopharma (TBPH) entered a strategic review after its sole pipeline candidate failed a pivotal Phase‑III trial, prompting a sharp stock drop from the low $20s to $13‑$14. The company, a single‑product pharma spun out a decade ago, relies on...
BREAKTHROUGH CURES By The Thousands: LigandForge Is Here.
The video spotlights three AI‑driven breakthroughs reshaping biomedicine: a tech‑entrepreneur in Australia used publicly available AI tools to design a custom mRNA cancer vaccine that reduced his dog Rosie’s tumor by 75%, researchers identified the circulating protein HMGB1 as a...
Pulmonary Fibrosis, Immune Responses & Guidance Proteins - The Herzog Lab at Yale School of Medicine
The Herzog Lab at Yale School of Medicine is investigating pulmonary fibrosis, a lethal lung disease characterized by progressive scarring that stiffens the organ and shortens life expectancy. Researchers argue that fibrosis results from an ongoing, maladaptive healing response after an...
Healthspan Vs. Lifespan - Are We Asking the Wrong Question? | Longevity Biomarker Summit Panel
The Longevity Biomarker Summit panel brought together policy leader Tina Woods, Buck Institute CEO Eric Verden, translational scientist Jasmine Smith, and Disney‑affiliated researcher Keith Kido to debate whether the field is asking the wrong question—healthspan versus lifespan. The speakers converged on...
Healey Community Q&A Webinar: March 12, 2026 | CNM-Au8 Expanded Access Update
The Healey Community Q&A webinar on March 12, 2026 featured Dr. Jinsey Andrews presenting interim results from the NIH‑funded CNM‑AU8 expanded access program (EAP) for amyotrophic lateral sclerosis (ALS). The program targets patients ineligible for traditional clinical trials, offering them...
Healey ALS MyMatch
The Shaun M. Healey and AMG Center for ALS at Massachusetts General Hospital unveiled ALS MyMatch, a precision‑medicine platform designed to overhaul early‑phase clinical trials for amyotrophic lateral sclerosis. By integrating a unified screening protocol that evaluates multiple biomarkers and...
Why "Mirror Cells" Could Reset Life on Earth
The video dramatizes a sci‑fi mission where "mirrored" agents infiltrate a body‑like corporation, using the concept of molecular chirality to illustrate a potential bio‑threat. It explains that most biomolecules exist in a single handedness—left‑handed (L) forms—while their mirror images (D)...
Nucleosome Remodelling | Nucleosome Model of Chromosome Csir Net Life Science
The video explains chromatin remodeling, focusing on nucleosome architecture and the epigenetic modifications that govern DNA accessibility. It describes how DNA is wrapped around an octamer of histone proteins, forming nucleosomes that compact the genome while allowing regulated access for...
It Takes a Community to End Tuberculosis
A new phase‑three trial of the M72 tuberculosis vaccine is underway across Africa and Asia, with roughly 20,000 volunteers, aiming to halt the progression from infection to disease. The effort is anchored in South Africa, where TB mortality remains among...
Zombie Cells Could Change Bioengineering
The video explains a breakthrough in synthetic biology where scientists performed whole‑genome transplantation, inserting an entire genome from one Mycoplasma species into a dead cell of another species. By first killing the recipient bacteria with a chemotherapy drug, they ensured...
Media Briefing: MRNA Vaccines
The Johns Hopkins Bloomberg School of Public Health hosted a media briefing to explain how messenger RNA (mRNA) vaccines work, their safety profile, and their expanding role beyond COVID‑19. Professors Andrew Pekosch and Gigi Granvall outlined the technology’s core advantage:...
IXICO CEO Says Milestone Medidata Collaboration Supports Growth Strategy
IXICO’s chief executive Bram Goorden announced a strategic partnership with Medidata, the multibillion‑dollar leader in electronic data capture and clinical‑trial services. The deal is presented as the first step in IXICO’s “tech‑bio” growth plan, aiming to blend the company’s proprietary...
What Does MDMA Therapy Actually Look Like? | Rachel Yehuda
Rachel Yehuda explains that MDMA‑assisted psychotherapy for PTSD is a structured, multi‑phase program rather than a one‑off drug experience. Patients undergo extensive preparation, discussing stuck points, hopes, and readiness before any medication is administered. The protocol currently approved for FDA...
How Your Circadian Rhythm Could Change How Effective Medical Treatments Are
The video explores how the body’s internal clock—its circadian rhythm—can dictate the success of medical interventions, especially cancer therapies. Researchers have observed that patients receiving chemotherapy or other treatments in the morning often experience better outcomes than those treated later...
Nyrada Phase 2 Trial Targets Heart Attack Damage
Nyrada Inc announced it will commence a Phase 2 trial of its lead candidate Zoltrip in Australia, enrolling 100 patients who have experienced a STEMI heart attack across seven sites. The study’s primary objective is to confirm safety while seeking...
AI Meets Biochemistry: Redefining the Lab with Robotic Experiments
The video outlines a Stanford‑led experiment where a reasoning‑type AI model was paired with a fully automated robotic laboratory to tackle a classic biochemistry challenge—self‑free protein synthesis, a process that extracts cellular contents and adds DNA to produce target proteins. The...
Commercializing CAR T Cell Therapy With Legend Biotech's Alan Bash
In a Business of Biotech interview, Legend Biotech’s President Alan Bash discusses the commercial trajectory of Carvykti, the J&J‑partnered CAR‑T therapy for multiple myeloma that received FDA approval in 2022 and now generates blockbuster revenues. Bash highlights the product’s Q4 2025...
Clarkston - The Secret to Biotech Launch Success
The video focuses on how pre‑commercial biotech firms can set themselves up for a successful product launch by rigorously mapping out sequencing, prioritization, and the necessary people, process, and technology capabilities. It emphasizes that a clear commercial strategy should be...
EphB2-Ephrin-B1 Signaling in Microglia and Implications for NeuroHIV
The seminar presented Dr. Marcus Call’s recent work on EphB2‑ephrin‑B1 signaling in microglia and its relevance to neuroHIV. While antiretroviral therapy has reduced systemic viral loads, roughly half of people living with HIV still develop neurocognitive impairment, ranging from asymptomatic...
Atrial Fibrillation Therapy in Patients with Stents (ADAPT AF-DES)
The New England Journal of Medicine’s ADAPT AF‑DES trial examined whether a non‑vitamin K antagonist oral anticoagulant (NOAC) alone could safely replace the conventional dual antithrombotic regimen of NOAC plus clopidogrel in patients with atrial fibrillation who had received a...
NEJM Clinician: Apixaban Vs. Rivaroxaban for Acute VTE
The New England Journal of Medicine published a head‑to‑head trial evaluating apixaban (Eliquis) against rivaroxaban (Xarelto) in 2,800 patients with acute pulmonary embolism or deep‑vein thrombosis. The study provides the first direct comparative safety and efficacy data for these two...
They Call It a Lottery Ticket. The Data Says Otherwise | The Hidden Alpha of Biotech
Biotech investing is portrayed as a lottery ticket, yet specialist investors argue persistent alpha exists. The conversation with DA Wallak explores how early‑stage biotech firms are valued using a “bag of options” framework that sums the net present value of...
Radiotherapeutics For CNS Cancers With Plus Therapeutics' Marc Hedrick, M.D.
In a recent Life Science Leader interview, Marc Hedrick, M.D., President and CEO of Plus Therapeutics, outlined the company’s strategic shift toward radiotherapeutics targeting central nervous system (CNS) malignancies. The discussion centered on the lead asset, Rayobic, a Re‑186 beta‑emitting...
Health Reporters React to "The Fugitive"
The video features health journalists using the 1993 thriller “The Fugitive” as a springboard to explore how a fictional pharmaceutical scandal would be reported today. They walk through the plot’s central drug, Provasic—originally called RDU90—described as a revolutionary, side‑effect‑free arterial...
Group Quebec - Nanosis A Nanomedicine Design Puzzle
Group Quebec’s BioNano Engineering Group unveiled Nanosis, a Tetris‑inspired educational game that lets players assemble nanoparticles, molecular linkers, and biomolecular ligands to navigate the body’s biological barriers. Each level mirrors a stage of nanomedicine delivery—from bloodstream circulation and immune evasion...
FDA & Rare Disease Drugs: Why Policy and Politics Are Heating Up
The episode focuses on the FDA’s new draft guidance designed to streamline approval pathways for ultra‑rare, often single‑patient, therapies. Host Jeff Buyers and guest Leslie Erlac discuss the policy shift against the backdrop of recent leadership turmoil, notably the departure...